The latest Business updates from the science industry
by Heather Hobbs
Lauda Announces
new.degree GmbH to Identify Temperature Control Innovation Opportunities
In the medium term, however, it is planned to move to the ‘Brainstation’ innovation centre planned by Lauda Managing Director,
Dr.Gunther Wobser, at Lauda railway station, the town that gives the company its name, in order to provide the creative space that is crucial to its success.
Manager of the newly founded
new.degree GmbH, Birgit Dillmann (centre), with members of her team.
Lauda Dr R Wobser GmbH & Co KG announces
new.degree GmbH, a new, wholly owned Lauda subsidiary, to deal with temperature control-related innovation activities outside the present core business. The new company is managed by Birgit Dillmann and comprises seven employees in Germany and abroad.
new.degree GmbH brings together Lauda start-up management, the Lauda innovation laboratory including the branch offi ce in Morgan Hill, USA, as well as the Lauda Digital Unit, which is responsible for digitalisation projects within Lauda. The Lauda internal ideas management scheme is also supported in the new company. The objective of the merger is to further professionalise and strategically develop the activities which have been developed so far.
new.degree GmbH is based at its current location in Lauda-Königshofen.
The core task of the new company is to identify innovation potentials relevant to temperature control outside Lauda’s current normal business activities, develop them into innovative solutions and test them in the market at an early stage. Potential approaches to this will be systematically generated by the analysis of trends and suitable search fi elds, uncovering opportunities for future-critical technologies, targeted collaboration with startups or also thanks to ideas provided via the internal idea management instrument. The innovation laboratory quickly and validly evaluates such ideas for their sales opportunities and innovation potential. Promising ideas are developed into so-called Minimum Viable Products using agile development methods such as Lean Startup and Design Thinking with the active involvement of potential users.
new.degree GmbH supports start-ups in their business development with relevant technology innovations and gives their business ideas the necessary initial momentum through joint pilot projects. In addition, the Lauda management innovation experts recommend strategic investments in promising start-ups on the basis of a comprehensive system. Lauda has so far successfully invested in three start-ups - watttron, ENER-IQ and Better Basics Laborbedarf.
More information online:
ilmt.co/PL/aVZj 54955pr@reply-direct.com
Financing to Progress Lead Therapeutic to Clinic
Following progress made by the company over the past 18 months, Adaptate Biotherapeutics, a developer of antibody- based therapeutics for modulation of gamma delta T cells, announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited, have together made a further equity investment of $18 million (circa. £13 million). This funding brings the total raised since Adaptate’s inception in late 2019 to $34 million (circa. £25 million).
The funds will be used to accelerate the company’s lead therapeutic antibody programme towards the clinic and to expand its internal product pipeline through expanded R&D activities. This will encompass planned expansion in recruitment, laboratory and offi ce space. The Company’s most advanced programmes are focussed on treatments for cancer patients with solid tumours.
Dr Natalie Mount, CEO of Adaptate Biotherapeutics, said: “The funding is a great vote of confi dence from our existing investors and testimony to the hard work and rapid progress we have made in the novel fi eld of gamma delta T cell targeting antibodies. We are excited to continue this growth path and to progress our unique therapeutic antibodies towards clinical trials where we look forward to them making an impact on the treatments available to cancer patients.”
More information online:
ilmt.co/PL/lJDo 55176pr@reply-direct.com
Dr Natalie Mount
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
